# Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.

> **NCT04213664** · — · UNKNOWN · sponsor: **Corporacion Parc Tauli** · enrollment: 4666 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Progression
- Lymphocyte Disorder
- Monocytosis
- Local Disease

## Interventions

- **OTHER:** prognosis

## Key facts

- **NCT ID:** NCT04213664
- **Lead sponsor:** Corporacion Parc Tauli
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-31
- **Primary completion:** 2020-01-02
- **Final completion:** 2020-01-31
- **Target enrollment:** 4666 (ESTIMATED)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04213664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04213664, "Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04213664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*